Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of lisaftoclax plus azacitidine in newly diagnosed older or chemotherapy-ineligible acute myeloid leukemia
CTR20241476Phase 3Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by Suzhou Yasheng Pharmaceutical. Started Jun 2024; status: active.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20241476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241476.